Comparison of palonosetron (PALO) plus dexamethasone on day 1, with or without dexamethasone on days 2 and 3, in the prevention of chemotherapy induced nausea and vomiting (CINV) in breast cancer patients treated with anthracycline/cyclophosphamide regimens

Abstract #4088 BACKGROUND PALO is a selective and potent serotonin antagonist, with a pharmacologically different structure and binding affinity compared to older 5-HT3 receptors antagonists. Multiple studies with PALO have demonstrated better efficacy in preventing emesis throughout the 5 days after moderately and highly emetogenic chemotherapy (CT) compared to ondansetron, dolasetron or granisetron. METHODS This was a phase 4, double-blind, randomized, multicenter, parallel study, in 300 CT naïve patients with breast cancer receiving cyclophosphamide Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4088.